Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025549 | 0.96 | L3MBTL1 (0.57) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14025553 | 0.96 | L3MBTL1 (0.62) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4071811 | 0.86 | L3MBTL1 (0.62) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14025561 | 0.85 | KEAP1 (0.71) | L3MBTL1SMN1; SMN2ALDH1A1LMNAKEAP1 | |
| SCHEMBL4743987 | 0.84 | PRMT1 (0.63) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1873887 | 0.83 | PRMT1 (0.77) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4064560 | 0.81 | L3MBTL1 (0.62) | L3MBTL1PRMT1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5032581 | 0.80 | PRMT1 (0.72) | L3MBTL1PRMT1ALDH1A1LMNAGAA | |
| SCHEMBL20267872 | 0.80 | L3MBTL1 (0.65) | L3MBTL1PRMT1ALDH1A1LMNAGAA | |
| SCHEMBL4067817 | 0.80 | CYP2C19 (0.61) | L3MBTL1PRMT1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | L3MBTL1 1552/4885PRMT1 126/4885SMN1; SMN2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.